Drugs / RO-14
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00629733 | Dec 2007 | — | Rovi Pharmaceuticals Laboratories | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO-14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00629733 ↗ |
| Modality | Other / unclassified | “new ultra low molecular weight heparin” NCT00629733 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00629733 ↗ |